NCT01462643View on ClinicalTrials.gov

Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Psoriasis
Interventions
DRUG

LAS41004

once daily, topical ointment, 100 microgram per day

Trial Locations (1)

22869

Investigational site, Schenefeld

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
collaborator

proDERM GmbH

INDUSTRY

lead

Almirall, S.A.

INDUSTRY